科华生物
(002022)
| 流通市值：34.81亿 | | | 总市值：34.82亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,428,075,213.95 | 1,904,222,528.93 | 1,396,475,774.51 | 833,147,693.69 |
| 营业收入 | 2,428,075,213.95 | 1,904,222,528.93 | 1,396,475,774.51 | 833,147,693.69 |
| 二、营业总成本 | 2,535,414,687.83 | 1,880,857,832.49 | 1,329,458,524.99 | 736,271,219.1 |
| 营业成本 | 1,399,855,969.4 | 1,058,730,070.33 | 762,787,408.91 | 442,543,620.3 |
| 税金及附加 | 14,549,071.01 | 10,098,534.46 | 7,196,947.44 | 3,836,571.34 |
| 销售费用 | 458,472,466.77 | 349,871,548.34 | 254,487,788.54 | 128,490,377.04 |
| 管理费用 | 408,497,161.56 | 268,115,666.36 | 178,483,304.26 | 81,310,165.54 |
| 研发费用 | 241,357,853.04 | 186,166,801.41 | 124,846,858.7 | 65,812,039.46 |
| 财务费用 | 12,682,166.05 | 7,875,211.59 | 1,656,217.14 | 14,278,445.42 |
| 其中:利息费用 | 43,742,300.34 | 32,371,285.68 | 21,188,752.17 | 10,245,731.73 |
| 其中:利息收入 | 30,980,785.71 | 22,925,767.73 | 19,130,203.42 | 7,954,256.41 |
| 加:公允价值变动收益 | 1,471,746.93 | - | - | - |
| 加:投资收益 | 22,936,968.85 | 19,416,291.02 | 14,010,705.59 | 7,014,732.49 |
| 资产处置收益 | 5,018,213.91 | 1,559,467.57 | 546,963.35 | -507,086.16 |
| 资产减值损失(新) | -171,167,059.71 | -20,630,813.71 | -16,498,208.98 | 813,568.2 |
| 信用减值损失(新) | -17,355,243.94 | -1,608,073.93 | 582,551.66 | 2,340,720.57 |
| 其他收益 | 87,107,494.76 | 57,096,908.25 | 40,534,416.42 | 10,547,704.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -179,327,353.08 | 79,198,475.64 | 106,193,677.56 | 117,086,114.1 |
| 加:营业外收入 | 1,554,498.7 | 409,105.18 | 240,713.9 | 287,638.46 |
| 减:营业外支出 | 7,835,980.72 | 4,341,331.52 | 2,032,138.72 | 1,028,112.58 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -185,608,835.1 | 75,266,249.3 | 104,402,252.74 | 116,345,639.98 |
| 减:所得税费用 | -8,623,725.6 | 26,696,679.4 | 26,598,317.2 | 19,171,340.63 |
| 六、净利润 | -176,985,109.5 | 48,569,569.9 | 77,803,935.54 | 97,174,299.35 |
| 持续经营净利润 | -176,985,109.5 | 48,569,569.9 | 77,803,935.54 | 97,174,299.35 |
| 归属于母公司股东的净利润 | -234,014,886.4 | -19,954,130.67 | 21,128,073.92 | 54,761,876.98 |
| 少数股东损益 | 57,029,776.9 | 68,523,700.57 | 56,675,861.62 | 42,412,422.37 |
| (一)基本每股收益 | -0.46 | -0.04 | 0.04 | 0.11 |
| (二)稀释每股收益 | -0.46 | -0.04 | 0.04 | 0.11 |
| 八、其他综合收益 | 5,095,342.54 | 15,889,170.35 | 23,703,323.59 | -2,293,123.09 |
| 归属于母公司股东的其他综合收益 | 677,590.41 | 14,118,920.97 | 19,010,904.23 | -1,933,888.65 |
| 九、综合收益总额 | -171,889,766.96 | 64,458,740.25 | 101,507,259.13 | 94,881,176.26 |
| 归属于母公司股东的综合收益总额 | -233,337,295.99 | -5,835,209.7 | 40,138,978.15 | 52,827,988.33 |
| 归属于少数股东的综合收益总额 | 61,447,529.03 | 70,293,949.95 | 61,368,280.98 | 42,053,187.93 |
| 公告日期 | 2024-03-23 | 2023-10-28 | 2023-08-17 | 2023-04-22 |
| 审计意见(境内) | 标准无保留意见 | | | |